Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

294 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Genomic Landscape of Malignant Peripheral Nerve Sheath Tumor‒Like Melanoma.
Muniz TP, Sorotsky H, Kanjanapan Y, Rose AAN, Araujo DV, Fortuna A, Ghazarian D, Kamil ZS, Pugh T, Mah M, Thiagarajah M, Torti D, Spreafico A, Hogg D. Muniz TP, et al. Among authors: hogg d. J Invest Dermatol. 2021 Oct;141(10):2470-2479. doi: 10.1016/j.jid.2021.03.016. Epub 2021 Apr 6. J Invest Dermatol. 2021. PMID: 33831431 Free article.
Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint Inhibitors.
Kelly D, Rose AAN, Muniz TP, Hogg D, Butler MO, Saibil SD, King I, Kamil ZS, Ghazarian D, Ross K, Iafolla M, Araujo DV, Waldron J, Laperriere N, Krema H, Spreafico A. Kelly D, et al. Among authors: hogg d. Cancers (Basel). 2021 Jul 20;13(14):3640. doi: 10.3390/cancers13143640. Cancers (Basel). 2021. PMID: 34298857 Free PMC article.
Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
Rose AAN, Armstrong SM, Hogg D, Butler MO, Saibil SD, Arteaga DP, Pimentel Muniz T, Kelly D, Ghazarian D, King I, Kamil ZS, Ross K, Spreafico A. Rose AAN, et al. Among authors: hogg d. J Immunother Cancer. 2021 Jan;9(1):e001642. doi: 10.1136/jitc-2020-001642. J Immunother Cancer. 2021. PMID: 33483342 Free PMC article.
Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2.
Nguyen LT, Saibil SD, Sotov V, Le MX, Khoja L, Ghazarian D, Bonilla L, Majeed H, Hogg D, Joshua AM, Crump M, Franke N, Spreafico A, Hansen A, Al-Habeeb A, Leong W, Easson A, Reedijk M, Goldstein DP, McCready D, Yasufuku K, Waddell T, Cypel M, Pierre A, Zhang B, Boross-Harmer S, Cipollone J, Nelles M, Scheid E, Fyrsta M, Lo CS, Nie J, Yam JY, Yen PH, Gray D, Motta V, Elford AR, DeLuca S, Wang L, Effendi S, Ellenchery R, Hirano N, Ohashi PS, Butler MO. Nguyen LT, et al. Among authors: hogg d. Cancer Immunol Immunother. 2019 May;68(5):773-785. doi: 10.1007/s00262-019-02307-x. Epub 2019 Feb 11. Cancer Immunol Immunother. 2019. PMID: 30747243 Free PMC article. Clinical Trial.
A flexible multiplex bead-based assay for detecting germline CDKN2A and CDK4 variants in melanoma-prone kindreds.
Lang JM, Shennan M, Njauw JC, Luo S, Bishop JN, Harland M, Hayward NK, Tucker MA, Goldstein AM, Landi MT, Puig S, Gruis NA, Bergman W, Bianchi-Scarra G, Ghiorzo P, Hogg D, Tsao H. Lang JM, et al. Among authors: hogg d. J Invest Dermatol. 2011 Feb;131(2):480-6. doi: 10.1038/jid.2010.331. Epub 2010 Nov 18. J Invest Dermatol. 2011. PMID: 21085193 Free PMC article.
294 results